JPWO2021055641A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021055641A5 JPWO2021055641A5 JP2022517166A JP2022517166A JPWO2021055641A5 JP WO2021055641 A5 JPWO2021055641 A5 JP WO2021055641A5 JP 2022517166 A JP2022517166 A JP 2022517166A JP 2022517166 A JP2022517166 A JP 2022517166A JP WO2021055641 A5 JPWO2021055641 A5 JP WO2021055641A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- group
- linker
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 125000005647 linker group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- -1 -C= CS (O) 2aryl Chemical group 0.000 claims description 10
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 10
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 9
- 150000003568 thioethers Chemical class 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 5
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 5
- 229910006095 SO2F Inorganic materials 0.000 claims description 5
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 5
- 229910006069 SO3H Inorganic materials 0.000 claims description 5
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims description 5
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000003852 triazoles Chemical class 0.000 claims description 5
- 108091007960 PI3Ks Proteins 0.000 claims description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 150000002019 disulfides Chemical class 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025095652A JP2025131780A (ja) | 2019-09-17 | 2025-06-09 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とする、がんならびに他の線維性疾患および炎症性疾患の画像化および治療の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901792P | 2019-09-17 | 2019-09-17 | |
| US62/901,792 | 2019-09-17 | ||
| PCT/US2020/051328 WO2021055641A1 (en) | 2019-09-17 | 2020-09-17 | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025095652A Division JP2025131780A (ja) | 2019-09-17 | 2025-06-09 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とする、がんならびに他の線維性疾患および炎症性疾患の画像化および治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548155A JP2022548155A (ja) | 2022-11-16 |
| JPWO2021055641A5 true JPWO2021055641A5 (https=) | 2023-09-25 |
| JP2022548155A5 JP2022548155A5 (https=) | 2023-09-25 |
Family
ID=74883518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517166A Pending JP2022548155A (ja) | 2019-09-17 | 2020-09-17 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とする、がんならびに他の線維性疾患および炎症性疾患の画像化および治療の方法 |
| JP2025095652A Pending JP2025131780A (ja) | 2019-09-17 | 2025-06-09 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とする、がんならびに他の線維性疾患および炎症性疾患の画像化および治療の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025095652A Pending JP2025131780A (ja) | 2019-09-17 | 2025-06-09 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とする、がんならびに他の線維性疾患および炎症性疾患の画像化および治療の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220409747A1 (https=) |
| EP (1) | EP4031184A4 (https=) |
| JP (2) | JP2022548155A (https=) |
| KR (1) | KR20220066098A (https=) |
| CN (1) | CN114901315B (https=) |
| AU (2) | AU2020348781B2 (https=) |
| BR (1) | BR112022005013A2 (https=) |
| CA (1) | CA3150890A1 (https=) |
| IL (1) | IL291386A (https=) |
| MX (1) | MX2022003215A (https=) |
| WO (1) | WO2021055641A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| US20230147962A1 (en) * | 2020-02-12 | 2023-05-11 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
| EP4132921A4 (en) * | 2020-04-09 | 2024-03-27 | Purdue Research Foundation | Pi3 kinase inhibitors and uses thereof |
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| AU2024235779A1 (en) * | 2023-03-10 | 2025-10-23 | Purdue Research Foundation | Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts |
| WO2026041108A1 (zh) * | 2024-08-23 | 2026-02-26 | 苏州博锐创合医药有限公司 | 基于环肽和共价弹头的化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071787B2 (en) * | 2009-03-13 | 2011-12-06 | National Health Research Institutes | Pyrrolidine compounds |
| CN103788071A (zh) * | 2012-11-01 | 2014-05-14 | 中国人民解放军第二军医大学 | N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途 |
| AU2017213404A1 (en) * | 2016-01-29 | 2018-09-20 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| CN116474108A (zh) * | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| US10966999B2 (en) * | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
| DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
-
2020
- 2020-09-17 WO PCT/US2020/051328 patent/WO2021055641A1/en not_active Ceased
- 2020-09-17 BR BR112022005013A patent/BR112022005013A2/pt unknown
- 2020-09-17 US US17/761,508 patent/US20220409747A1/en active Pending
- 2020-09-17 AU AU2020348781A patent/AU2020348781B2/en active Active
- 2020-09-17 CA CA3150890A patent/CA3150890A1/en active Pending
- 2020-09-17 KR KR1020227012076A patent/KR20220066098A/ko active Pending
- 2020-09-17 EP EP20865602.5A patent/EP4031184A4/en active Pending
- 2020-09-17 JP JP2022517166A patent/JP2022548155A/ja active Pending
- 2020-09-17 MX MX2022003215A patent/MX2022003215A/es unknown
- 2020-09-17 CN CN202080079485.1A patent/CN114901315B/zh active Active
-
2022
- 2022-03-15 IL IL291386A patent/IL291386A/en unknown
-
2025
- 2025-06-09 JP JP2025095652A patent/JP2025131780A/ja active Pending
-
2026
- 2026-02-10 AU AU2026200943A patent/AU2026200943A1/en not_active Abandoned